Anebulo Pharmaceuticals (ANEB)
(Real Time Quote from BATS)
$1.83 USD
-0.20 (-10.04%)
Updated Aug 28, 2024 03:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Income Statements
Fiscal Year end for Anebulo Pharmaceuticals, Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 12 | 7 | 4 | 0 |
Income After Depreciation & Amortization | 0 | -12 | -7 | -4 | 0 |
Non-Operating Income | NA | 0 | 0 | -27 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -12 | -7 | -30 | 0 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -12 | -7 | -30 | 0 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -12 | -7 | -30 | 0 |
Depreciation Footnote | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -12 | -7 | -4 | 0 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -12 | -7 | -4 | 0 |
Earnings Per Share Data | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Average Shares | NA | 25.08 | 23.35 | 13.61 | NA |
Diluted EPS Before Non-Recurring Items | NA | -0.47 | -0.29 | -1.37 | NA |
Diluted Net EPS (GAAP) | NA | -0.47 | -0.29 | -2.83 | -0.01 |
Fiscal Year end for Anebulo Pharmaceuticals, Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.67 | 2.76 | 2.54 | 2.50 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.67 | -2.76 | -2.54 | -2.50 |
Non-Operating Income | NA | 0.07 | 0.07 | 0.06 | -0.09 |
Interest Expense | NA | 0.06 | 0.03 | 0.00 | 0.00 |
Pretax Income | NA | -1.65 | -2.72 | -2.48 | -2.50 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.65 | -2.72 | -2.48 | -2.50 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.65 | -2.72 | -2.48 | -2.50 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 25.93 | 25.79 | 25.63 | 25.63 |
Diluted EPS Before Non-Recurring Items | NA | -0.06 | -0.11 | -0.10 | -0.10 |
Diluted Net EPS (GAAP) | NA | -0.06 | -0.11 | -0.10 | -0.10 |